Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Tuberculosis | Research

Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis

Authors: Patricia Bartholomay, Rejane Sobrino Pinheiro, Fernanda Dockhorn, Daniele Maria Pelissari, Wildo Navegantes de Araújo

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Treatment outcomes were evaluated of a cohort of new pulmonary tuberculosis (TB) cases that were rifampicin resistant, multidrug-resistant, or extensively resistant during 2013 and 2014 in Brazil. The objective of this study is to identify factors associated with unfavorable treatment outcomes for drug-resistant TB cases.

Methods

The Brazilian Special Tuberculosis Treatment Information System (SITE-TB) was the main data source. The independent variables were classified into four blocks (block I: individual characteristics; block II: clinical characteristics and proposed treatment; block III: treatment follow-up characteristics; and block IV: TB history). The category of successful therapeutic outcome was compared with lost to follow-up, failure, and death. Considering the multiple outcomes as the dependent variable, the odds ratios (OR) and its respective 95% confidence interval (95% CI) were estimated by multinomial logistic regression.

Results

After applying the exclusion criteria, 980 (98.8%) individuals were included in the study. Of these, 621 (63.4%) had successful treatment, 163 (16.6%) lost to follow-up, 76 (7.8%) failed, and 120 (12.2%) died. Important factors associated with lost to follow-up in the final model included use of illicit drugs (OR = 2.5 95% CI: 1.57–3.82). Outcome failure was associated with having disease in both lungs (OR = 2.0; 95% CI: 1.09–3.62) and using more than one or not using injectable medication (OR = 2.8; 95% CI: 1.05–7.69). Major factors for the death outcome were at least 60 years old (OR = 3.4; 95% CI: 1.90–6.03) and HIV positive (OR = 2.7; 95% CI: 1.45–4.83).

Conclusions

The factors associated with unfavorable treatment outcomes were different. Some of these factors are specific to each outcome, which reflects the complexity of providing care to these individuals.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. WHO. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
2.
go back to reference Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J. 2015;45(1):150–60.CrossRef Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J. 2015;45(1):150–60.CrossRef
3.
go back to reference Brasil. Manual de recomendações para o controle da tuberculose no Brasil. 2a edição. Brasília: Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica; 2019. Brasil. Manual de recomendações para o controle da tuberculose no Brasil. 2a edição. Brasília: Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica; 2019.
4.
go back to reference Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC Public Health. 2019;19(1):165.CrossRef Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC Public Health. 2019;19(1):165.CrossRef
5.
go back to reference Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718.CrossRef Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718.CrossRef
6.
go back to reference Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7): e1002595.CrossRef Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7): e1002595.CrossRef
8.
go back to reference Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584–93.CrossRef Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584–93.CrossRef
9.
go back to reference Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):4980.CrossRef Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):4980.CrossRef
11.
go back to reference Bartholomay P, Pinheiro RS, Pelissari DM, Arakaki-Sanchez D, Dockhorn F, Rocha JL, et al. Sistema de Informação de Tratamentos Especiais de Tuberculose (SITE-TB): histórico, descrição e perspectivas. Epidemiol E Serviços Saúde. 2019;28: e2018158.CrossRef Bartholomay P, Pinheiro RS, Pelissari DM, Arakaki-Sanchez D, Dockhorn F, Rocha JL, et al. Sistema de Informação de Tratamentos Especiais de Tuberculose (SITE-TB): histórico, descrição e perspectivas. Epidemiol E Serviços Saúde. 2019;28: e2018158.CrossRef
13.
go back to reference Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLOS Med. 2014;11(12): e1001766.CrossRef Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLOS Med. 2014;11(12): e1001766.CrossRef
14.
go back to reference Arbex MA, Varella M de CL, Siqueira HR de, Mello FAF de. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol Publicaça̋o. 2010;36(5):641–56. Arbex MA, Varella M de CL, Siqueira HR de, Mello FAF de. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol Publicaça̋o. 2010;36(5):641–56.
15.
go back to reference Hosmer DW, Lemeshow S. Goodness-of-fit tests for the multiple logistic regression model. Commun Stat Methods. 1980;9:1043–69.CrossRef Hosmer DW, Lemeshow S. Goodness-of-fit tests for the multiple logistic regression model. Commun Stat Methods. 1980;9:1043–69.CrossRef
16.
go back to reference do Prado TN, Rajan JV, Miranda AE, Dias EdS, Cosme LB, Possuelo LG, et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. Braz J Infect Dis. 2017;21(2):162–70.CrossRef do Prado TN, Rajan JV, Miranda AE, Dias EdS, Cosme LB, Possuelo LG, et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. Braz J Infect Dis. 2017;21(2):162–70.CrossRef
17.
go back to reference Tupasi TE, Garfin AMCG, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis. 2016;22(3):491–502.CrossRef Tupasi TE, Garfin AMCG, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis. 2016;22(3):491–502.CrossRef
18.
go back to reference Bhering M, Kritski A. Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000–2016. Rev Panam Salud Pública. 2020;44: e178.CrossRef Bhering M, Kritski A. Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000–2016. Rev Panam Salud Pública. 2020;44: e178.CrossRef
19.
go back to reference Mackenbach JP, Kunst AE. Measuring the magnitude of socio-economic inequalities in health: an overview of available measures illustrated with two examples from Europe. Soc Sci Med 1982. 1997;44(6):757–71. Mackenbach JP, Kunst AE. Measuring the magnitude of socio-economic inequalities in health: an overview of available measures illustrated with two examples from Europe. Soc Sci Med 1982. 1997;44(6):757–71.
21.
go back to reference Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet. 2010;375(9728):1814–29.CrossRef Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet. 2010;375(9728):1814–29.CrossRef
22.
go back to reference Bhatt R, Chopra K, Vashisht R. Impact of integrated psycho-socio-economic support on treatment outcome in drug resistant tuberculosis—a retrospective cohort study. Indian J Tuberc. 2019;66(1):105–10.CrossRef Bhatt R, Chopra K, Vashisht R. Impact of integrated psycho-socio-economic support on treatment outcome in drug resistant tuberculosis—a retrospective cohort study. Indian J Tuberc. 2019;66(1):105–10.CrossRef
23.
go back to reference Gegia M, Kalandadze I, Madzgharashvili M, Furin J. Developing a human rights-based program for tuberculosis control in Georgian prisons. Health Hum Rights. 2011;13(2):E73-81.PubMed Gegia M, Kalandadze I, Madzgharashvili M, Furin J. Developing a human rights-based program for tuberculosis control in Georgian prisons. Health Hum Rights. 2011;13(2):E73-81.PubMed
24.
go back to reference Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36(3):584–93.CrossRef Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J. 2010;36(3):584–93.CrossRef
26.
go back to reference Garrido MdS, Penna ML, Perez-Porcuna TM, de Souza AB, Marreiro LdS, Albuquerque BC, et al. Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: a case control-study. PLoS ONE. 2012;7(6): e39134.CrossRef Garrido MdS, Penna ML, Perez-Porcuna TM, de Souza AB, Marreiro LdS, Albuquerque BC, et al. Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: a case control-study. PLoS ONE. 2012;7(6): e39134.CrossRef
27.
go back to reference Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, et al. Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc. 2014;11(5):712–8.CrossRef Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, et al. Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc. 2014;11(5):712–8.CrossRef
28.
go back to reference Wang J, Pang Y, Jing W, Chen W, Guo R, Han X, et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist. 2019;12:763–70.CrossRef Wang J, Pang Y, Jing W, Chen W, Guo R, Han X, et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist. 2019;12:763–70.CrossRef
30.
go back to reference Pinheiro RS, Viacava F, Travassos C, Brito AdS. Gênero, morbidade, acesso e utilização de serviços de saúde no Brasil. Ciênc Amp Saúde Coletiva. 2002;7(4):687–707.CrossRef Pinheiro RS, Viacava F, Travassos C, Brito AdS. Gênero, morbidade, acesso e utilização de serviços de saúde no Brasil. Ciênc Amp Saúde Coletiva. 2002;7(4):687–707.CrossRef
31.
go back to reference Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS ONE. 2011;6(7): e20436.CrossRef Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS ONE. 2011;6(7): e20436.CrossRef
32.
go back to reference Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018;4:5.CrossRef Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M. Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018;4:5.CrossRef
33.
go back to reference Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9): a017863.CrossRef Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9): a017863.CrossRef
34.
go back to reference Bhering M, Duarte R, Kritski A. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis. 2021;25(4):292–8.CrossRef Bhering M, Duarte R, Kritski A. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis. 2021;25(4):292–8.CrossRef
35.
go back to reference Gler MT, Guilatco R, Caoili JC, Ershova J, Cegielski P, Johnson JL. Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg. 2013;89(5):943–9.CrossRef Gler MT, Guilatco R, Caoili JC, Ershova J, Cegielski P, Johnson JL. Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg. 2013;89(5):943–9.CrossRef
36.
go back to reference WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. (End TB Strategic). WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. (End TB Strategic).
Metadata
Title
Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis
Authors
Patricia Bartholomay
Rejane Sobrino Pinheiro
Fernanda Dockhorn
Daniele Maria Pelissari
Wildo Navegantes de Araújo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06756-7

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.